Home » Bispecific Antibodies Market

Bispecific Antibodies Market By Type (Immunoglobulin G (IgG) Like Molecule, Non Immunoglobulin G (IgG) Like Molecule), by Application (Oncology, Autoimmune Disease, Others) – Growth, Future Prospects & Competitive Analysis, 2018 – 2026

Price: $4999

Published: | Report ID: 1669 | Report Format : PDF

Industry Outlook

The bispecific antibodies market is set to grow with a compounded annual growth rate (CAGR) of 5.9% during the forecast period from 2018 to 2026. According to the research findings presented by the World Health Organization (WHO), in 2018, cancer was responsible for the deaths of approximately 9.6 million people throughout the globe. The severe adverse effects related to chemotherapy led to the development of bispecific antibodies for the treatment of cancer. Currently, two drugs are approved by the U.S. Food and Drug Administration: catumaxomab and blinatumomab. Thirty bispecific antibodies are in the pipeline and are undergoing clinical trial studies. The competition exerted by monoclonal antibodies for the treatment of the same disease condition acts as a major limitation for the bispecific antibody market’s growth.

Design Element 2

Access crucial information at unmatched prices!

Request your free sample report today & start making informed decisions powered by Credence Research!

Download Free Sample
CTA Design Element 3

Market Synopsis

The IgG-like molecule market is driven by a longer serum half-life and an excellent cytotoxicity profile.

An immunoglobulin G (IgG)-like molecule is leading the type segment for the bispecific antibodies market. An IgG-like molecule such as catumaxomab (Fresenius Biotech and Trion Pharma) is widely employed for the treatment of malignant ascites due to its inherent features, such as its longer serum half-life and excellent cytotoxicity profile. Non-IgG-like molecules will be the fastest-growing market during the forecast period owing to the recent launch of blinatumomab (Amgen, Inc.) for the treatment of refractory B-cell acute lymphoblastic leukemia on account of its smaller half-life and enhanced tissue penetration characteristics.

Severe adverse effects related to the current treatment regime and the burgeoning requirement for targeted drug delivery drive the oncology market’s growth.

Oncology currently dominates the application segment of the market for bispecific antibodies. The factors responsible for its growth are the severe adverse effects related to the current treatment regimen and the burgeoning requirement of targeted drug delivery for the treatment of cancer. Bispecific antibodies have the ability to cater to the current requirement in cancer treatment by redirecting immune effector cells towards tumor cells, blocking signaling pathways, and targeting tumor angiogenesis. Autoimmune diseases such as plaque psoriasis and rheumatoid arthritis will be treated in the near future by employing bispecific antibodies such as IL-6RHAS (Ablynx) and IL-17A/F (Merck Group) that block the proinflammatory cytokines. A few bispecific antibodies are in the pipeline, which will be utilized for the treatment of ailments such as wet age-related macular degeneration (AMD) and idiopathic pulmonary fibrosis.

Increasing mortality and a lack of effective treatment for cancer drive the bispecific antibody market in North America.

North America is currently leading the geographical segment for the bispecific antibody market. The major attributes responsible for the dominance of North America are increasing mortality and a lack of effective treatment for cancer. According to the Centers for Disease Control and Prevention (CDC), cancer is the second-largest cause of mortality in the United States, resulting in 1 in 4 deaths due to the disease. The bispecific antibody market in Europe is driven by factors such as increased funding by government healthcare agencies in drug discovery and cancer prevention programs. The domicile of key players such as Merck Group, F. Hoffmann-La Roche AG, and Janssen Global Services, LLC, etc., provides impetus to the growth of bispecific antibodies in Europe. Asia Pacific is set to register positive growth during the forecast period of 2018–2026 owing to the rising prevalence of cancer and a supportive regulatory environment for the approval and distribution of bispecific antibodies.

Periods of History and Forecast

This research report presents the analysis of each segment from 2016 to 2026, considering 2017 as the base year for the research. The compound annual growth rate (CAGR) for each of the respective segments is calculated for the forecast period from 2018 to 2026.

Report Scope by Segments

In the scope of the report, the market is segmented as follows:

Biopharmaceutical companies providing bispecific antibodies are Amgen, Inc.; Ablynx; Eli Lilly and Company; F.Hoffman La-Roche AG; Janssen Global Services, LLC; Merck Group; Merrimack Pharmaceuticals; Neovii Biotech; OncoMed Pharmaceuticals, Inc.; and Regeneron Pharmaceuticals.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Key questions are answered in this report.

  • Who are the key biopharmaceutical companies manufacturing bispecific antibodies?
  • What are the drivers, opportunities, and restraints pertaining to the market for bispecific antibodies?
  • What is the disease etiology of different forms of cancer, and what is the mechanism of action of bispecific antibodies?
  • Which type is the largest and fastest growing in the market for bispecific antibodies?
  • Which application is the largest and fastest growing in the bispecific antibody market?
  • Which regional segment is the leading and fastest-growing one in the bispecific antibodies market?

Chapter 1. Preface
1.1. Report Scope and Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I-Secondary Research
1.3.2. Phase II-Primary Research
1.3.3. Approach Adopted
1.3.4. Top-down Approach
1.3.5. Bottom-up Approach
1.3.6. Phase III-Expert Panel Review
1.3.7. Assumptions
1.4. Market Segmentation

Chapter 2. Executive Summary
2.1. Global BA Market Portraiture
2.2. Global BA Market, by Type, 2017 (US$ Mn)
2.3. Global BA Market, by Application, 2017 (US$ Mn)
2.4. Global BA Market, by Geography, 2017 (US$ Mn)

Chapter 3. BA Market: Dynamics and Future Outlook
3.1. Market Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.5. Attractive Investment Proposition, by Geography, 2017
3.6. Competitive Analysis: Global BA Market, by Key Players, 2017

Chapter 4. Global BA Market, by Type
4.1. Overview
4.2. Immunoglobulin G (IgG) Like Molecule
4.3. Non Immunoglobulin G (IgG) Like Molecule

Chapter 5. Global BA Market, by Application
5.1. Overview
5.2. Oncology
5.3. Autoimmune Disease
5.4. Others

Chapter 6. Global BA Market, by Geography
6.1. Overview
6.2. North America BA Market Analysis, 2016 – 2026
6.2.1. North America BA Market, by Type, 2016 – 2026 (US$ Mn)
6.2.2. North America BA Market, by Application, 2016 – 2026 (US$ Mn)
6.2.3. North America BA Market, by Country, 2016 – 2026 (US$ Mn)
6.2.3.1. U.S.
6.2.3.2. Canada
6.3. Europe BA Market Analysis, 2016 – 2026
6.3.1. Europe BA Market, by Type, 2016 – 2026 (US$ Mn)
6.3.2. Europe BA Market, by Application, 2016 – 2026 (US$ Mn)
6.3.3. Europe BA Market, by Country/Region, 2016 – 2026 (US$ Mn)
6.3.3.1. U.K.
6.3.3.2. Germany
6.3.3.3. Rest of Europe
6.4. Asia Pacific BA Market Analysis, 2016 – 2026
6.4.1. Asia Pacific BA Market, by Type, 2016 – 2026 (US$ Mn)
6.4.2. Asia Pacific BA Market, by Application, 2016 – 2026 (US$ Mn)
6.4.3. Asia Pacific BA Market, by Country/Region, 2016 – 2026 (US$ Mn)
6.4.3.1. China
6.4.3.2. Japan
6.4.3.3. Rest of Asia Pacific
6.5. Latin America BA Market Analysis, 2016 – 2026
6.5.1. Latin America BA Market, by Type, 2016 – 2026 (US$ Mn)
6.5.2. Latin America BA Market, by Application, 2016 – 2026 (US$ Mn)
6.5.3. Latin America BA Market, by Country/Region, 2016 – 2026 (US$ Mn)
6.5.3.1. Brazil
6.5.3.2. Mexico
6.5.3.3. Rest of Latin America
6.6. Middle East and Africa BA Market Analysis, 2016 – 2026
6.6.1. MEA BA Market, by Type, 2016 – 2026 (US$ Mn)
6.6.2. MEA BA Market, by Application, 2016 – 2026 (US$ Mn)
6.6.3. MEA BA Market, by Country/Region, 2016 – 2026 (US$ Mn)
6.6.3.1. GCC
6.6.3.2. Rest of MEA

Chapter 7. Company Profiles
7.1. Amgen, Inc.
7.1.1. Business Description
7.1.2. Financial Information (Subject to data availability)
7.1.3. Type Portfolio
7.1.4. News Coverage
7.2. Ablynx
7.3. Eli Lilly and Company
7.4. F. Hoffmann-La Roche AG
7.5. Janssen Global Services, LLC
7.6. Merck Group
7.7. Merrimack Pharmaceuticals
7.8. Neovii Biotech
7.9. OncoMed Pharmaceuticals, Inc.
7.10. Regeneron Pharmaceuticals

List of Figures

FIG. 1 Bispecific Antibodies (BA) Market: Research Methodology
FIG. 2 BA Market Segmentation
FIG. 3 Global BA Market, by Type, 2017 (US$ Mn)
FIG. 4 Global BA Market, by Application, 2017 (US$ Mn)
FIG. 5 Global BA Market, by Geography, 2017 (US$ Mn)
FIG. 6 Attractive Investment Proposition: by Geography, 2017
FIG. 7 Competitive Analysis: Global BA Market, by Key Players, 2017
FIG. 8 Global IgG Like Molecule Market for Bispecific Antibodies, 2016 – 2026 (US$ Mn)
FIG. 9 Global Non IgG Like Molecule Market for Bispecific Antibodies, 2016 – 2026 (US$ Mn)
FIG. 10 Global Oncology Market for Bispecific Antibodies, 2016 – 2026 (US$ Mn)
FIG. 11 Global Autoimmune Disease Market for Bispecific Antibodies, 2016 – 2026 (US$ Mn)
FIG. 12 Global Other Applications Market for Bispecific Antibodies, 2016 – 2026 (US$ Mn)
FIG. 13 U.S. BA Market, 2016 – 2026 (US$ Mn)
FIG. 14 Canada BA Market, 2016 – 2026 (US$ Mn)
FIG. 15 U.K. BA Market, 2016 – 2026 (US$ Mn)
FIG. 16 Germany BA Market, 2016 – 2026 (US$ Mn)
FIG. 17 Rest of Europe BA Market, 2016 – 2026 (US$ Mn)
FIG. 18 China BA Market, 2016 – 2026 (US$ Mn)
FIG. 19 Japan BA Market, 2016 – 2026 (US$ Mn)
FIG. 20 Rest of Asia Pacific BA Market, 2016 – 2026 (US$ Mn)
FIG. 21 Brazil BA Market, 2016 – 2026 (US$ Mn)
FIG. 22 Mexico BA Market, 2016 – 2026 (US$ Mn)
FIG. 23 Rest of Latin America BA Market, 2016 – 2026 (US$ Mn)
FIG. 24 GCC BA Market, 2016 – 2026 (US$ Mn)
FIG. 25 Rest of MEA BA Market, 2016 – 2026 (US$ Mn)

List of Tables

TABLE 1 Global Bispecific Antibodies (BA) Market Portraiture
TABLE 2 Global BA Market, by Type, 2016 – 2026 (US$ Mn)
TABLE 3 Global BA Market , by Application, 2016 – 2026 (US$ Mn)
TABLE 4 Global BA Market, by Geography, 2016 – 2026 (US$ Mn)
TABLE 5 North America BA Market, by Type, 2016 – 2026 (US$ Mn)
TABLE 6 North America BA Market, by Application, 2016 – 2026 (US$ Mn)
TABLE 7 North America BA Market, by Country, 2016 – 2026 (US$ Mn)
TABLE 8 Europe BA Market, by Type, 2016 – 2026 (US$ Mn)
TABLE 9 Europe BA Market, by Application, 2016 – 2026 (US$ Mn)
TABLE 10 Europe BA Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 11 Asia Pacific BA Market, by Type, 2016 – 2026 (US$ Mn)
TABLE 12 Asia Pacific BA Market, by Application, 2016 – 2026 (US$ Mn)
TABLE 13 Asia Pacific BA Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 14 Latin America BA Market, by Type, 2016 – 2026 (US$ Mn)
TABLE 15 Latin America BA Market, by Application, 2016 – 2026 (US$ Mn)
TABLE 16 Latin America BA Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 17 Middle East and Africa BA Market, by Type, 2016 – 2026 (US$ Mn)
TABLE 18 Middle East and Africa BA Market, by Application, 2016 – 2026 (US$ Mn)
TABLE 19 Middle East and Africa BA Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 20 Amgen, Inc.: Company Snapshot (Business Description; Financial Information; Application Portfolio; Key Developments)
TABLE 21 Ablynx: Company Snapshot (Business Description; Financial Information; Application Portfolio; Key Developments)
TABLE 22 Eli Lilly and Company: Company Snapshot (Business Description; Financial Information; Application Portfolio; Key Developments)
TABLE 23 F.Hoffman-La Roche AG: Company Snapshot (Business Description; Financial Information; Application Portfolio; Key Developments)
TABLE 24 Janssen Global Services, LLC.: Company Snapshot (Business Description; Financial Information; Application Portfolio; Key Developments)
TABLE 25 Merck Group: Company Snapshot (Business Description; Financial Information; Application Portfolio; Key Developments)
TABLE 26 Merrimack Pharmaceuticals: Company Snapshot (Business Description; Financial Information; Application Portfolio; Key Developments)
TABLE 27 Neovii Biotech: Company Snapshot (Business Description; Financial Information; Application Portfolio; Key Developments)
TABLE 28 OncoMed Pharmaceuticals, Inc.: Company Snapshot (Business Description; Financial Information; Application Portfolio; Key Developments)
TABLE 29 Regeneron Pharmaceuticals: Company Snapshot (Business Description; Financial Information; Application Portfolio; Key Developments)

Frequently Asked Questions

What is the size of Bispecific Antibodies Market?

The market for Bispecific Antibodies Market is expected to reach US$ XX Mn by 2026.

What is the Bispecific Antibodies Market CAGR?

The Bispecific Antibodies Market is expected to see significant CAGR growth over the coming years, at 5.9%.

What is the Forecast period considered for Bispecific Antibodies Market?

The report is forecasted from 2018-2026.

What is the base year considered for Bispecific Antibodies Market?

The base year of this report is 2017.

Who are the major players in this market?

Ablynx; Eli Lilly and Company; F.Hoffman La-Roche AG; Janssen Global Services, LLC; Merck Group; Merrimack Pharmaceuticals; Neovii Biotech; OncoMed Pharmaceuticals, Inc. are some of the major players in the global market.

Neuromyelitis Optica Spectrum Disorder (NMOSD) Market

Published:
Report ID: 33712

Tracheitis Treatment Market

Published:
Report ID: 33694

Neuralgia Treatment Market

Published:
Report ID: 33681

Clostridioides Difficile (C. diff) Treatment Market

Published:
Report ID: 33667

Sphingosine-1-Receptor Modulators Drugs Market

Published:
Report ID: 33649

Neuromyelitis Optica Therapy Market

Published:
Report ID: 33583

Pediatric Bladder Treatment Market

Published:
Report ID: 33540

Neurotrophic Keratitis Treatment Market

Published:
Report ID: 33425

Precision Medicine Market

Published:
Report ID: 11123

Eosinophilic Pneumonia Treatment Market

Published:
Report ID: 5486

Myelodysplastic Syndrome Market

Published:
Report ID: 32821

US Retail Pharmacy Market

Published:
Report ID: 32801

Purchase Options

$2999
Delivery Format: Excel.
$4999
Designed for the individual purchaser.
$6999
Users located at a single corporate site or regional office.
$7999
Allowed for unlimited sharing globally within one company.
Smallform of Sample request

Have a question?

User Profile

Don’t settle for less – trust Mitul to help you find the best solution.

Report delivery within 24 to 48 hours

– Other Info –

What people say?-

User Review

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –

Phone

+91 6232 49 3207


support

24/7 Research Support


sales@credenceresearch.com

– Research Methodology –

Going beyond the basics: advanced techniques in research methodology

– Trusted By –

Pepshi, LG, Nestle
Motorola, Honeywell, Johnson and johnson
LG Chem, SIEMENS, Pfizer
Unilever, Samsonite, QIAGEN